BIOLIFE SOLUTIONS INC (BLFS)
BIOLIFE SOLUTIONS INC (BLFS)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 1,186 | 11,070 | 621 | -16,286 |
| Loss on disposal of property and equipment, net | NaN | -11 | 0 | 0 |
| Impairment of intangible assets | NaN | 0 | NaN | NaN |
| Ipr&d expense | NaN | 0 | 0 | 15,521 |
| Impairment of long-lived assets | NaN | 0 | NaN | NaN |
| Loss on disposal of global cooling | NaN | NaN | 0 | 0 |
| Gain on settlement of global cooling escrow | NaN | 0 | NaN | NaN |
| Depreciation | 374 | 261 | 636 | 1,356 |
| Amortization of intangible assets | 325 | 325 | 699 | 1,410 |
| Amortization of loan costs | NaN | 0 | NaN | NaN |
| Stock-based compensation | 4,806 | 7,077 | 5,904 | 10,012 |
| Non-cash lease (benefit) expense | -188 | -118 | 1,323 | 670 |
| Deferred income tax expense | 9 | 0 | 14 | 51 |
| Change in fair value of contingent consideration | NaN | 0 | NaN | NaN |
| Change in fair value of equity investment and other | NaN | 942 | 41 | 0 |
| Accretion of available-for-sale investments | 122 | 201 | 230 | 305 |
| Net gain on disposal of subsidiaries | NaN | 10,324 | NaN | NaN |
| Gain on disposal of assets held for rent, net | 0 | 0 | -167 | -343 |
| Accounts receivable, trade, net | 5,104 | -1,938 | 782 | 892 |
| Inventories | 2,679 | 2,331 | 197 | -1,260 |
| Prepaid expenses and other assets | -3,218 | 462 | 3,000 | -423 |
| Accounts payable | 2,206 | -952 | -679 | -455 |
| Investment in convertible promissory note | NaN | 0 | 2,000 | NaN |
| Accrued expenses and other current liabilities | -4,400 | 680 | 1,564 | -3,388 |
| Proceeds from sale of divested entities | NaN | 23,516 | NaN | NaN |
| Sales taxes payable | -148 | -1,385 | 105 | -625 |
| Payments on divestiture of global cooling | NaN | 0 | 0 | 0 |
| Warranty liability | NaN | 5 | NaN | NaN |
| Purchases of property and equipment | NaN | NaN | 3,302 | 1,918 |
| Purchases of intangible assets | NaN | 0 | NaN | NaN |
| Other | 26 | 264 | 0 | 0 |
| Investment in ipr&d | NaN | 0 | 0 | 10,221 |
| Net cash (used in) provided by operating activities | -491 | 4,916 | 6,104 | 9,095 |
| Purchases of available-for-sale securities | 20,430 | 36,670 | 13,090 | 64,303 |
| Proceeds from sale of available-for-sale securities | 2,331 | 3,238 | 1,836 | 1,755 |
| Maturities of available-for-sale securities | 16,436 | 15,412 | 10,962 | 8,390 |
| Purchases of assets held for rent | 0 | 101 | 373 | 412 |
| Purchases of property and equipment | 167 | 9,478 | NaN | NaN |
| Net cash used in investing activities | -1,830 | 1,137 | -5,967 | -66,709 |
| Payments on equipment loans | NaN | 0 | 0 | 0 |
| Issuance of common stock | NaN | 0 | NaN | NaN |
| Proceeds from exercises of common stock options | 190 | 0 | 0 | 18 |
| Payments on term loans | 2,500 | 2,500 | 2,500 | 5,000 |
| Proceeds from financed insurance premium | NaN | 0 | 0 | NaN |
| Payment of tax withholding on vesting of shares | 5,588 | NaN | NaN | NaN |
| Payments on financed insurance premium | 0 | 0 | 67 | 908 |
| Other | 3 | 4 | 9 | 20 |
| Net cash used in financing activities | -7,895 | -2,496 | -2,558 | -5,870 |
| Net decrease in cash and cash equivalents | -10,216 | 3,557 | -2,421 | -63,484 |
| Cash and cash equivalents beginning of period | 33,038 | 29,481 | NaN | NaN |
| Cash and cash equivalents at beginning of period | NaN | NaN | 95,386 | NaN |
| Effects of currency translation on cash and cash equivalents | NaN | 0 | NaN | NaN |
| Cash and cash equivalents at end of period | NaN | NaN | 29,481 | NaN |
| Cash and cash equivalents end of period | 22,822 | 33,038 | NaN | NaN |